AzTrials
AzTrials

Community-acquired Pneumonia, Influenza, COVID-19Phase 3REMAP-CAPNCT02735707

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

A Phase 3 study testing Ceftriaxone, Moxifloxacin or Levofloxacin and Piperacillin-tazobactam in people with Community-acquired Pneumonia, Influenza, COVID-19, run by UMC Utrecht at 408 sites in 29 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Ceftriaxone, Moxifloxacin or Levofloxacin and Piperacillin-tazobactam
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20,000 participants
Where
408 sitesin 29 countries
Study dates
11 Apr 2016to Feb 2028
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

REMAP-CAP PLATFORM INCLUSION CRITERIA:

  1. Adult patient admitted to an ICU for severe CAP within 48 hours of hospital admission with:
  2. symptoms or signs or both that are consistent with lower respiratory tract infection AND
  3. Radiological evidence of new onset consolidation (in patients with pre-existing radiological changes, evidence of new infiltrate)
  4. Up to 48 hours after ICU admission, receiving organ support with one or more of:
  5. Non-invasive or Invasive ventilatory support;
  6. Receiving infusion of vasopressor or inotropes or both

PLATFORM EXCLUSION CRITERIA:

  1. Healthcare-associated pneumonia:
  2. Prior to this illness, is known to have been an inpatient in any healthcare facility within the last 30 days
  3. Resident of a nursing home or long term care facility
  4. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
  5. Previous participation in this REMAP within the last 90 days

REMAP-COVID PLATFORM INCLUSION CRITERIA

  1. Adult patients (≥ 18 years) admitted to hospital with acute illness due to suspected or proven pandemic infection.

REMAP-COVID PLATFORM EXCLUSION CRITERIA

  1. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
  2. Patient is expected to be discharged from hospital today or tomorrow
  3. More than 14 days have elapsed while admitted to hospital with symptoms of an acute illness due to suspected or proven pandemic infection.
  4. Previous participation in this REMAP within the last 90 days

DOMAIN-SPECIFIC ELIGIBLE CRITERIA:

Each domain may have additional eligibility criteria. Refer to the study website for more information (www.remapcap.org).

Trial locations and contacts

408 sites in 29 countries. Contact the study team or a site near you to ask about taking part.

Cameron Green, MSc contact

info@remapcap.org

Svenja Peters, MSc contact

EU.remapcap@umcutrecht.nl

408 sites in 29 countries

United Kingdom153 sites, 66 recruiting

  • Aberdeen Royal Infirmary

    Aberdeen, Scotland, AB25 2ZN

    Completed

  • Neville Hall Hospital

    Abergavenny, Wales, NP7 7EG

    Active, not recruiting

  • Antrim Area Hospital

    Antrim, Northern Ireland, BT41 2RL

    Paul Johnston, MD

    Recruiting

  • Basildon Hospital

    Basildon, England, SS16 5NL

    Active, not recruiting

  • Basingstoke and North Hampshire Hospital

    Basingstoke, England, RG24 9NA

    Irena Grecu, MD

    Recruiting

  • Royal United Hospital, Bath

    Bath, England, BA1 3NG

    Active, not recruiting

  • Royal Victoria Hospital Belfast

    Belfast, Northern Ireland, BT12 6BA

    Michael McGinlay, MD

    Recruiting

  • Mater Hospital

    Belfast, Northern Ireland, BT14 6AB

    Michael McGinlay, MD

    Recruiting

  • Belfast City Hospital

    Belfast, Northern Ireland, BT9 7AB

    Michael McGinlay, MD

    Recruiting

  • Ulster Hospital

    Belfast, BT16 1RH

    Christopher Murray, MD

    Recruiting

  • Queen Elizabeth Hospital Birmingham

    Birmingham, England, B15 2TH

    Dhruv Parekh

    Recruiting

  • Birmingham City Hospital

    Birmingham, England, B18 7QH

    Jonathan Hulme

    Recruiting

  • Royal Blackburn Teaching Hospital

    Blackburn, England, BB2 3HH

    Srikanth Chukkambotla, MD

    Recruiting

  • Glan Clwyd Hospital

    Bodelwyddan, Wales, LL18 5UJ

    Active, not recruiting

  • Pilgrim Hospital ULHT

    Boston, England, PE21 9QS

    Suspended

  • Royal Bournemouth Hospital

    Bournemouth, England, BH7 7DW

    Active, not recruiting

  • Princess of Wales Hospital

    Bridgend, Wales, CF31 1RQ

    Active, not recruiting

  • Royal Sussex County Hospital

    Brighton, England, BN2 5BE

    Suspended

  • Southmead Hospital

    Bristol, England, BS10 5NB

    Suspended

  • Bristol Royal Infirmary

    Bristol, England, BS2 8EX

    Active, not recruiting

  • Bristol Royal Childrens Hospital

    Bristol, BS2 8BJ

    Jolanta Bernatoniene, MD

    Recruiting

  • Queen's Hospital, Burton

    Burton-on-Trent, England, DE13 0RB

    Active, not recruiting

  • Fairfield General Hospital

    Bury, BL9 7TD

    Andrew Claxton, MD

    Recruiting

  • Royal Papworth Hospital

    Cambridge, England, CB2 0AY

    Active, not recruiting

  • Addenbrookes Hospital

    Cambridge, England, CB2 0QQ

    Active, not recruiting

  • Cardiff and Vale University Hospital Wales

    Cardiff, Wales, CF14 4XW

    Active, not recruiting

  • North Cumberland Infirmary

    Carlisle, England, CA2 7HY

    Suspended

  • Glangwilli Hospital

    Carmarthen, Wales, SA31 2AF

    Suspended

  • St Peter's Hospital

    Chertsey, England, KT16 0P

    Active, not recruiting

  • Countess of Chester Hospital

    Chester, England, CH2 1UL

    Active, not recruiting

  • Chesterfield Royal Hospital

    Chesterfield, England, S44 5BL

    Euan Mackay

    Recruiting

  • Colchester Hospital

    Colchester, England, CO4 5JL

    Mohamed Ramali

    Recruiting

  • University Hospital Coventry

    Coventry, England, CV2 2DX

    Active, not recruiting

  • Leighton Hospital

    Crewe, CW1 4QJ

    Richard Lowsby, MD

    Recruiting

  • Grange University Hospital

    Cwmbran, Wales, NP44 8YN

    Active, not recruiting

  • Darlington Memorial Hospital

    Darlington, England, DL3 6HX

    Suspended

  • Darent Valley Hospital

    Dartford, England, DA2 8DA

    Withdrawn

  • Dorset County Hospital

    Dorchester, DT1 2JY

    Completed

  • Russells Hall Hospital

    Dudley, England, DY1 2HQ

    Active, not recruiting

  • Ninewells Hospital

    Dundee, Scotland, DD1 9SY

    James Chambers, MD

    Recruiting

  • Royal Infirmary of Edinburgh

    Edinburgh, Scotland, EH16 4SA

    Thomas Craven, MD

    Recruiting

  • Royal Devon and Exeter Hospital

    Exeter, England, Ex2 5DW

    Suspended

  • Frimley Park Hospital

    Frimley, England, GU16 7 UJ

    Suspended

  • Queen Elizabeth Hospital Gateshead

    Gateshead, England, NE9 6SX

    Active, not recruiting

  • Medway Maritime Hospital

    Gillingham, England, ME7 5NY

    Completed

  • Glasgow Royal Infirmary

    Glasgow, Scotland, G4 0SF

    Kathryn Puxty, MD

    Recruiting

  • Queen Elizabeth University Hospital, Glasgow

    Glasgow, Scotland, G51 4TF

    Malcolm Sim, MD

    Recruiting

  • Gloucester Royal Hospital

    Gloucester, GL1 3NN

    Completed

  • James Paget University Hospital

    Great Yarmouth, England, NR31 6LA

    Completed

  • Royal Surrey County Hospital

    Guildford, England, GU2 7XX

    Ben Creagh-Brown

    Recruiting

  • Northwick Park Hospital

    Harrow, England, HA1 3UJ

    Active, not recruiting

  • The Princess Royal Hospital Haywards Heath

    Haywards Heath, RH16 4EX

    Active, not recruiting

  • Hereford County Hospital

    Hereford, England, HR1 2ER

    Charlotte Small

    Recruiting

  • Barnet Hospital

    High Barnet, England, EN5 3DJ

    Active, not recruiting

  • Huddersfield Royal Infirmary

    Huddersfield, England, HD3 3EA

    Active, not recruiting

  • King George Hospital

    Ilford, England, IG3 8YB

    Active, not recruiting

  • Ipswich Hospital

    Ipswich, England, IP4 5PD

    Withdrawn

  • Kettering Hospital

    Kettering, England, NN16 8UZ

    Dhinesh Sundaran

    Recruiting

  • Leeds General Infirmary

    Leeds, England, LS9 7TF

    Active, not recruiting

  • St. James University Hospital

    Leeds, LS9 7TF

    E Paramasivam, MD

    Recruiting

  • Leicester Royal Infirmary

    Leicester, England, LE1 5WW

    Suspended

  • Glenfield Hospital

    Leicester, England, LE3 9QP

    Suspended

  • Lincoln County Hospital

    Lincoln, England, LN2 5QY

    Suspended

  • Liverpool Heart and Chest Hospital

    Liverpool, England, L14 3PE

    Completed

  • Alder Hey Hospital

    Liverpool, England, L14 5AB

    Completed

  • Royal Liverpool University Hospital

    Liverpool, England, L7 8XP

    Active, not recruiting

  • University Hospital Aintree

    Liverpool, England, L9 7AL

    Suspended

  • Croydon University Hospital

    London, England, CR7 7YE

    Active, not recruiting

  • Royal London Hospital

    London, England, E1 1FR

    Active, not recruiting

  • Whipps Cross Hospital

    London, England, E11 1NR

    Active, not recruiting

  • Newham University Hospital

    London, England, E13 8SL

    Active, not recruiting

  • St Bartholomew's Hospital

    London, England, EC1A 7BE

    Active, not recruiting

  • North Middlesex University Hospital

    London, England, N18 1QX

    Active, not recruiting

  • Royal Free Hospital

    London, England, NW3 2QG

    Active, not recruiting

  • St Thomas Hospital

    London, England, SE1 7EH

    Marlies Ostermann

    Recruiting

  • Guy's Hospital

    London, England, SE1 9RT

    Active, not recruiting

  • Queen Elizabeth Hospital, Woolwich

    London, England, SE18 4QH

    Active, not recruiting

  • King's College Hospital

    London, England, SE5 9RS

    Phillip Hopkins

    Recruiting

  • St George's University Hospital

    London, England, SW17 0QT

    Susannah Leaver

    Recruiting

  • Royal Marsden Hospital

    London, England, SW3 6JJ

    Active, not recruiting

  • Royal Brompton Hospital

    London, England, SW3 6NP

    Active, not recruiting

  • Hammersmith Hospital

    London, England, W12 0HS

    Stephen Brett

    Recruiting

  • St Mary's Hospital

    London, England, W2 1NY

    Anthony Gordon

    Recruiting

  • Charing Cross Hospital

    London, England, W6 8RF

    David Antcliffe

    Recruiting

  • Homerton Hospital

    London, E9 6SR

    Suspended

  • University College London Hospital

    London, NW1 2BU

    Michael Marks, MD

    Recruiting

  • Chelsea and Westminster Hospital

    London, SW10 9NH

    Roger Davies, MD

    Recruiting

  • Altnagelvin Hospital

    Londonderry, Northern Ireland, BT47 6SB

    Adrian Donnelly, MD

    Recruiting

  • Luton and Dunstable University Hospital

    Luton, England, LU4 0DZ

    Suspended

  • Maidstone Hospital

    Maidstone, England, ME16 9QQ

    David Golden, MD

    Recruiting

  • Manchester Royal Infirmary

    Manchester, England, M13 9WL

    Suspended

  • The Christie Hospital

    Manchester, England, M20 4BX

    Completed

  • Wythenshawe Hospital

    Manchester, England, M23 9LT

    Suspended

  • North Manchester General Hospital

    Manchester, England, M8 5RB

    Active, not recruiting

  • Queen Elizabeth and Queen Mother Hospital

    Margate, CT9 4AN

    Suspended

  • Arrowe Park Hospital

    Metropolitan Borough of Wirral, England, CH49 5PE

    Craig Denmade, MD

    Recruiting

  • The James Cook University Hospital

    Middlesbrough, England, TS4 3BW

    Jeremy Henning, MD

    Recruiting

  • Milton Keynes University Hospital

    Milton Keynes, England, MK6 5LD

    Richard Stewart, MD

    Recruiting

  • Royal Victoria Infirmary, Newcastle

    Newcastle, England, NE1 4LP

    Suspended

  • Newcastle Freeman Hospital

    Newcastle, England, NE7 7DN

    Suspended

  • Newcastle Royal Victoria Infirmary (Paediatrics)

    Newcastle upon Tyne, NE1 4LP

    Marieke Emonts, MD

    Recruiting

  • Royal Gwent Hospital

    Newport, Wales, NP20 2UB

    Suspended

  • North Tyneside General Hospital

    North Shields, Ne29 8NH

    Suspended

  • Northampton General Hospital

    Northampton, England, NN1 5BD

    Suspended

  • Norfolk and Norwich University Hospital

    Norwich, England, NR4 7UY

    Completed

  • City Hospital Nottingham

    Nottingham, England, NG5 1PB

    Daniel Harvey, MD

    Recruiting

  • Queen's Medical Centre - Nottingham University Hospitals NHS Trust

    Nottingham, England, NG7 2UH

    Daniel Harvey, MD

    Recruiting

  • George Eliot Hospital

    Nuneaton, England, CV10 7DJ

    Active, not recruiting

  • Royal Oldham Hospital

    Oldham, England, Ol1 2JH

    Redmond Tully, MD

    Recruiting

  • Princess Royal University Hospital

    Orpington, England, BR6 8ND

    Suspended

  • John Radcliffe Hospital

    Oxford, England, OX3 9DU

    Active, not recruiting

  • Royal Alexandra Hospital

    Paisley, Scotland, PA2 9PN

    Kevin Rooney, MD

    Recruiting

  • Derriford Hospital

    Plymouth, England, PL6 8DH

    Nikitas Nikitas, MD

    Recruiting

  • Royal Glamorgan Hospital

    Pont-y-clun, Wales, CF72 8XR

    Active, not recruiting

  • Poole Hospital NHS Foundation Trust

    Poole, England, BH15 2JB

    Henrik Reschreiter, MD

    Recruiting

  • Queen Alexandra Hospital

    Portsmouth, England, PO6 3LY

    David Pogson, MD

    Recruiting

  • Whiston Hospital

    Prescot, England, L35 5DR

    Terminated

  • Royal Preston Hospital

    Preston, England, PR2 9HT

    Suspended

  • Royal Berkshire Hospital

    Reading, England, RG1 5AN

    Andrew Walden, MD

    Recruiting

  • Alexandra Hospital, Redditch

    Redditch, England, B98 7UB

    Active, not recruiting

  • Queen's Hospital Romford

    Romford, England, RM7 0AG

    Active, not recruiting

  • Rotherham Hospital

    Rotherham, England, S60 2UD

    Anil Hormis, MD

    Recruiting

  • Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust

    Royal Tunbridge Wells, England, TN2 4QJ

    David Golden, MD

    Recruiting

  • Salford Royal Hospital

    Salford, England, M6 8HD

    Paul Dark, MD

    Recruiting

  • Salisbury District Hospital

    Salisbury, England, SP2 8BJ

    Phil Donnison, MD

    Recruiting

  • Royal Hallamshire Hospital

    Sheffield, England, S10 2JF

    Gary Mills, MD

    Recruiting

  • Northern General Hospital

    Sheffield, England, S5 7AU

    Gary Mills, MD

    Recruiting

  • Wexham Park Hospital

    Slough, England, SL2 4HL

    Active, not recruiting

  • South Tyneside District Hospital

    South Shields, England, NE34 0PL

    Alistair Roy, MD

    Recruiting

  • Southampton General Hospital

    Southampton, England, SO16 6YD

    Ahilanandan Dushianthan, MD

    Recruiting

  • Stepping Hill Hospital

    Stockport, England, SK2 7JE

    Hywel Garrard, MD

    Recruiting

  • University Hospital of North Tees

    Stockton-on-Tees, England, TS19 8PE

    Farooq Brohi, MD

    Recruiting

  • Royal Stoke University Hospital

    Stoke-on-Trent, England, ST4 6QG

    Ramprasad Matsa, MD

    Recruiting

  • Sunderland Royal Hospital

    Sunderland, England, SR4 7TP

    Alistair Roy, MD

    Recruiting

  • King's Mill Hospital

    Sutton in Ashfield, England, NG17 4JL

    Sandaruwan Herath, MD

    Recruiting

  • Morriston Hospital

    Swansea, Wales, SA6 6NL

    Active, not recruiting

  • Great Western Hospital

    Swindon, England, SN3 6BB

    Active, not recruiting

  • Western General Hospital

    Swindon, England, SN3 6BB

    Jonathan Rhodes, MD

    Recruiting

  • Musgrove Park Hospital

    Taunton, England, TA1 5DA

    Richard Innes, MD

    Recruiting

  • Torbay Hospital

    Torquay, England, TQ2 7AA

    Adam Revill, MD

    Recruiting

  • Royal Cornwall Hospital

    Truro, England, TR1 3LJ

    Michael Spivey, MD

    Recruiting

  • Harefield Hospital

    Uxbridge, England, UB9 6JH

    Completed

  • Warwick Hospital

    Warwick, CV34 5BW

    Active, not recruiting

  • Watford General Hospital

    Watford, England, WD18 0HB

    Valarie Page, MD

    Recruiting

  • Sandwell General Hospital

    West Bromwich, B71 4HJ

    Jonathan Hulme, MD

    Recruiting

  • Southend Hospital

    Westcliff-on-Sea, England, ISS0 0RY

    Active, not recruiting

  • West Cumberland Hospital

    Whitehaven, England, CA28 8JG

    Withdrawn

  • Royal Albert Edward Infirmary

    Wigan, England, WN1 2NN

    Active, not recruiting

  • Royal Hampshire County Hospital

    Winchester, England, SO22 5DG

    Irina Grecu, MD

    Recruiting

  • New Cross Hospital Wolverhampton

    Wolverhampton, England, WV10 0QP

    Active, not recruiting

  • Worcestershire Royal Hospital

    Worcester, England, WR5 1DD

    Active, not recruiting

  • Wrexham Maelor Hospital

    Wrexham, Wales, LL13 7TD

    David Southern, MD

    Recruiting

  • York Teaching Hospital

    York, England, Y031 8HE

    Joseph Carter, MD

    Recruiting

Other trials in United Kingdom

Australia59 sites, 59 recruiting

  • Royal Adelaide Hospital

    Adelaide, South Australia, 5000

    Recruiting

  • The Queen Elizabeth Hospital

    Adelaide, South Australia, 5011

    Recruiting

  • Lyell McEwin Hospital

    Adelaide, South Australia, 5112

    Recruiting

  • Ballarat Base Hospital

    Ballarat, Victoria, 3350

    Recruiting

  • Bankstown-Lidcombe Hospital

    Bankstown, New South Wales, 2200

    Recruiting

  • Flinders Medical Centre

    Bedford Park, South Australia, 5042

    Recruiting

  • Bendigo Hospital

    Bendigo, Victoria, 3550

    Recruiting

  • Casey Hospital

    Berwick, Victoria, 3806

    Recruiting

  • Sunshine Coast University Hospital

    Birtinya, Queensland, 4575

    Not yet recruiting

  • Blacktown Hospital

    Blacktown, New South Wales, 2148

    Recruiting

  • Box Hill Hospital

    Box Hill, Victoria, 3128

    Recruiting

  • The Prince Charles Hospital

    Brisbane, Queensland, 4032

    Recruiting

  • Mater Hospital Brisbane

    Brisbane, Queensland, 4101

    Recruiting

  • Princess Alexandra Hospital

    Brisbane, Queensland, 4102

    Recruiting

  • Caboolture Hospital

    Caboolture, Queensland, 4510

    Recruiting

  • Campbelltown Hospital

    Campbelltown, New South Wales, 2560

    Recruiting

  • Canberra Hospital

    Canberra, Australian Capital Territory, 2605

    Recruiting

  • Sutherland Hospital

    Caringbah, New South Wales, 2229

    Recruiting

  • Monash Medical Centre

    Clayton, Victoria, 3168

    Recruiting

  • Concord Hospital

    Concord, New South Wales, 2139

    Recruiting

  • Queen Elizabeth II Jubilee Hospital

    Coopers Plains, Queensland, 4110

    Recruiting

  • Dandenong Hospital

    Dandenong, Victoria, 3175

    Recruiting

  • Royal Darwin Hospital,

    Darwin, Northern Territory, 0810

    Not yet recruiting

  • Dubbo Base Hospital

    Dubbo, New South Wales, 2830

    Recruiting

  • Angliss Hospital

    Ferntree Gully, Victoria, 3156

    Not yet recruiting

  • Footscray Hospital

    Footscray, Victoria, 3011

    Recruiting

  • Northern Beaches Hospital

    Frenchs Forest, New South Wales, 2086

    Recruiting

  • University Hosptial Geelong

    Geelong, Victoria, 3220

    Recruiting

  • Nepean Hospital

    Kingswood, New South Wales, 2750

    Recruiting

  • St. George Hospital

    Kogarah, New South Wales, 2217

    Recruiting

  • Launceston Hospital

    Launceston, Tasmania, 7250

    Recruiting

  • Liverpool Hospital

    Liverpool, New South Wales, 2170

    Recruiting

  • Logan Hospital

    Logan City, Queensland, 4129

    Not yet recruiting

  • The Alfred Hospital

    Melbourne, Victoria, 3004

    Recruiting

  • Royal Melbourne Hospital

    Melbourne, Victoria, 3050

    Recruiting

  • St Vincent's Hospital Melbourne

    Melbourne, Victoria, 3065

    Recruiting

  • St John of God Hospital Midland

    Midland, Western Australia, 6056

    Recruiting

  • St John of God Hospital Murdoch

    Murdoch, Western Australia, 6150

    Not yet recruiting

  • John Hunter Hospital

    Newcastle, New South Wales, 2305

    Recruiting

  • Orange Health Service

    Orange, New South Wales, 2800

    Not yet recruiting

  • Royal Perth Hospital

    Perth, Western Australia, 6000

    Recruiting

  • Sir Charles Gairdner Hospital

    Perth, Western Australia, 6009

    Recruiting

  • Fiona Stanley Hospital

    Perth, Western Australia, 6150

    Recruiting

  • Redcliffe Hospital

    Redcliffe, Queensland, 4020

    Not yet recruiting

  • Maroondah Hospital

    Ringwood East, Victoria, 3135

    Recruiting

  • Rockhampton Hospital

    Rockhampton, Queensland, 4700

    Not yet recruiting

  • Gold Coast University Hospital

    Southport, Queensland, 4215

    Recruiting

  • St John of God Subiaco

    Subiaco, Western Australia, 6008

    Recruiting

  • Sunshine Hospital

    Sunshine, Victoria, 3021

    Recruiting

  • St Vincent's Hospital Sydney

    Sydney, New South Wales, 2010

    Recruiting

  • Prince of Wales Hospital

    Sydney, New South Wales, 2031

    Recruiting

  • Royal Prince Alfred Hospital

    Sydney, New South Wales, 2050

    Not yet recruiting

  • Royal North Shore Hospital

    Sydney, New South Wales, 2065

    Recruiting

  • Wollongong Hospital

    Sydney, New South Wales, 2500

    Recruiting

  • Toowoomba Hospital

    Toowoomba, Queensland, 4350

    Recruiting

  • Townsville Hospital

    Townsville, Queensland, 4814

    Recruiting

  • Wagga Wagga Base Hospital

    Wagga Wagga, New South Wales, 2650

    Not yet recruiting

  • Werribee Mercy Hospital

    Werribee, Victoria, 3030

    Recruiting

  • Westmead Hospital

    Westmead, New South Wales, 2145

    Recruiting

Other trials in Australia

Canada40 sites, 32 recruiting

  • William Osler Health System

    Brampton, Ontario, L6R 3J7

    Alexandra Binnie, MD

    Recruiting

  • Brantford General Hospital

    Brantford, Ontario, N3R 1G9

    Brenda Reeve, MD

    Recruiting

  • Foothills Medical Centre

    Calgary, Alberta, T2W 1S7

    Active, not recruiting

  • Peter Lougheed Centre

    Calgary, Alberta, T2W 1S7

    Active, not recruiting

  • Rockyview General Hospital

    Calgary, Alberta, T2W 1S7

    Active, not recruiting

  • South Health Campus

    Calgary, Alberta, T2W 1S7

    Active, not recruiting

  • Royal Alexandra Hospital, Alberta

    Edmonton, Alberta, T5H 3V9

    Demetrios Kutsogiannis, MD

    Recruiting

  • University of Alberta Hospital

    Edmonton, Alberta, T6G 2C8

    Wendy Sligl, MD

    Recruiting

  • Dr. Everett Chalmers Regional Hospital

    Fredericton, New Brunswick, E3B 4R3

    Zeeshan Aslam, MD

    Not yet recruiting

  • The Moncton Hospital

    Fredericton, New Brunswick, E3B 4R3

    Daniel Smyth, MD

    Not yet recruiting

  • The Saint John General Hospital

    Fredericton, New Brunswick, E3B 4R3

    Stephen Robinson, MD

    Not yet recruiting

  • Hamilton general Hospital

    Hamilton, Ontario, L8L 8E7

    Alison Fox-Robichaud, MD

    Recruiting

  • Juravinski Hospital

    Hamilton, Ontario, L8L 8E7

    Bram Rochwerg, MD

    Recruiting

  • St. Joseph's Healthcare Hamilton

    Hamilton, Ontario, L8N 4A6

    Deborah Cook, MD

    Recruiting

  • Kingston Health Sciences Centre

    Kingston, Ontario, K7L 2V7

    Active, not recruiting

  • Grand River Hospital

    Kitchener, Ontario, N2G 4K9

    Theresa Liu, MD

    Recruiting

  • St Mary's General Hospital

    Kitchener, Ontario, N2M 1B2

    Rebecca Kruisselbrink, MD

    Recruiting

  • CIUSS Chaudieres-Appalaches (Levis)

    Lévis, Quebec, G6V 3Z1

    Patrick Archambault, MD

    Not yet recruiting

  • Hospital Maisonneuve-Rosemont

    Montreal, Quebec, H1T 2M4

    Active, not recruiting

  • Hôpital Fleury

    Montreal, Quebec, H2B 1K3

    Thomas Hemmerling, MD

    Not yet recruiting

  • Centre Hospitalier de l'Universite de Montreal

    Montreal, Quebec, H2X 0A9

    Michael Chasse, MD

    Recruiting

  • McGill University Health Centre

    Montreal, Quebec, H3H 2R9

    Kosar Khwaja, MD

    Recruiting

  • Hopital du Sacre-Coeur de Montreal

    Montreal, Quebec, H4J 1C5

    Martin Albert, MD

    Recruiting

  • The Ottawa Hospital

    Ottawa, Ontario, K1H 8L6

    Lauralyn McIntyre, MD

    Recruiting

  • CHU de Québec - Université Laval

    Québec, Quebec, G1R 2J6

    Alexis Turgeon, MD

    Recruiting

  • IUCPQ-UL

    Québec, Quebec, G1V 4G5

    Francois Lellouche, MD

    Recruiting

  • Niagara Health

    Saint Catharines, Ontario, L2S 0A9

    Jennifer Tsang, MD

    Recruiting

  • Regina General Hospital

    Saskatoon, Saskatchewan, S7K 0M7

    Eric Sy, MD

    Recruiting

  • Centre Hospitalier de l'Université de Sherbrooke

    Sherbrooke, Quebec, J1J 3H5

    Francois Lamontagne, MD

    Recruiting

  • Surrey Memorial Hospital

    Surrey, British Columbia, V3V 1Z2

    Anish Mitra, MD

    Not yet recruiting

  • Thunder Bay General Hospital

    Thunder Bay, Ontario, P7B 6V4

    Active, not recruiting

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, M4N 3M5

    Rob Fowler, MD

    Recruiting

  • St. Michael's Hospital Unity Health Toronto

    Toronto, Ontario, M5B 1W8

    John Marshall, MD

    Recruiting

  • Mount Sinai Hospital

    Toronto, Ontario, M5G 1X5

    Sangeeta Mehta, MD

    Recruiting

  • Toronto General Hospital

    Toronto, Ontario, M5G 2C4

    Lorenzo del Sorbo, MD

    Recruiting

  • Toronto Western Hospital

    Toronto, Ontario, M5T 2S8

    Elizabeth Wilcox, MD

    Recruiting

  • St Joseph's Health Centre

    Toronto, Ontario, M6R 1B5

    Active, not recruiting

  • St Boniface General Hospital

    Winnipeg, Manitoba, R2H 2A6

    Ryan Zarychanski, MD

    Recruiting

  • Health Sciences Centre Winnipeg

    Winnipeg, Manitoba, R3A 1R9

    Ryan Zarychanski, MD

    Recruiting

  • Grace Hospital

    Winnipeg, Manitoba, R3J 3M7

    Gloria Vazquez-Grande, MD

    Recruiting

Other trials in Canada

France24 sites, 13 recruiting

  • CH Argenteuil

    Argenteuil, 95107

    Active, not recruiting

  • Centre Hospitalier Henri Mondor d'Aurillac

    Aurillac, 15000

    Completed

  • Beauvais General Hospital

    Beauvais, 60000

    Active, not recruiting

  • Hopital Nord Franche-Comte

    Belfort, 90400

    Suspended

  • Centre hospitalier Bethune Beuvry

    Béthune, 62660

    Christophe Vinsonneau, MD

    Recruiting

  • Ambroise Pare Hospital

    Boulogne-Billancourt, 92100

    Antoine Vieillard Baron, MD

    Recruiting

  • CH de Dax

    Dax, 40100

    Adrien Auvet, MD

    Recruiting

  • Centre Hospitalier de Dieppe

    Dieppe, 76202

    Peierre-Louis Declercq, MD

    Recruiting

  • CHU Dijon Bourgogne

    Dijon, 21000

    Jean-Pierre Quenot, MD

    Recruiting

  • Hopital Simone Veil Eaubonne

    Eaubonne, 95600

    Active, not recruiting

  • Sud Essonne Hospital Etampes

    Étampes, 91150

    Active, not recruiting

  • Hospital Raymond Poincare

    Garches, 92380

    Djillali Annane, MD

    Recruiting

  • CHD Vendee

    La Roche-sur-Yon, 85000

    Gwenael Colin, MD

    Recruiting

  • Centre Hospitalier Le Mans

    Le Mans, 72027

    Christophe Guitton, MD

    Recruiting

  • CHU Dupuytren

    Limoges, 87000

    Francois Bruno, MD

    Recruiting

  • Centre Hospitalier de Melun

    Melun, 77000

    Active, not recruiting

  • Centre Hospitalier Layne - Mont-de-Marsan

    Mont-de-Marsan, 40024

    Arnaud Sement, MD

    Recruiting

  • Centre Hospitalier des Pays de Morlaix

    Morlaix, 29600

    Pierre Yves Egreteau, MD

    Recruiting

  • CHR d'Orleans

    Orléans, 45100

    Active, not recruiting

  • Lariboisiere Hospital

    Paris, 75010

    Active, not recruiting

  • Hopital Tenon

    Paris, 75020

    Active, not recruiting

  • Nouvel Hopital Civil Strasbourg

    Strasbourg, 67000

    Ferhat Meziani, MD

    Recruiting

  • Hopital de Hautepierre Strasbourg

    Strasbourg, 67200

    Active, not recruiting

  • CHRU Tours Hopital Bretonneau

    Tours, 37000

    Emmanuelle Mercier, MD

    Recruiting

Other trials in France

Netherlands19 sites, 10 recruiting

  • Jeroen Bosch Ziekenhuis

    's-Hertogenbosch

    Koen Simons, M.D.

    Recruiting

  • ZGT Almelo

    Almelo, 7609PP

    Bastiaan Wittekamp, MD

    Recruiting

  • Meander Medisch Centrum

    Amersfoort

    Laura van Gulik, M.D.

    Recruiting

  • OLVG

    Amsterdam, 1091AC

    Active, not recruiting

  • Rijnstate Hospital

    Arnhem, 6815AD

    Robert-Jan Hassing, MD

    Recruiting

  • Deventer Hospital

    Deventer, 7416SE

    Active, not recruiting

  • Ziekenhuis Gelderse Vallei

    Ede, 6716RP

    Active, not recruiting

  • Maxima Medisch Centrum Eindhoven

    Eindhoven, 5631BM

    Active, not recruiting

  • Martini Hospital Groningen

    Groningen

    Withdrawn

  • University Medical Center Groningen

    Groningen

    Active, not recruiting

  • Medisch Centrum Leeuwarden

    Leeuwarden, 8934AD

    Active, not recruiting

  • Leiden University Medical Center

    Leiden

    Evert De Jonge, Prof.

    Recruiting

  • Canisius Wilhelmina Ziekenhuis

    Nijmegen

    Oscar Hoiting, M.D.

    Recruiting

  • Radboud University Medical Center

    Nijmegen

    Frank van de Veerdonk, Prof.

    Recruiting

  • Laurentius Hospital

    Roermond, 6043CV

    Active, not recruiting

  • Maasstad Ziekenhuis

    Rotterdam, 3079DZ

    Corstiaan den Uil, MD

    Recruiting

  • Hagaziekenhuis

    The Hague, 2545AA

    Thomas Ottens, MD

    Recruiting

  • Bernhoven Hospital

    Uden, 5406PT

    Active, not recruiting

  • University Medical Center Utrecht

    Utrecht, 3584 CX

    Marc Bonten, Prof.

    Lennie Derde, MD

    Recruiting

Other trials in Netherlands

Germany17 sites

  • Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie

    Berlin, 10117

    Withdrawn

  • Vivantes Klinikum Neukölln

    Berlin, 12351

    Completed

  • Charite Universitätsmedizin Berlin

    Berlin, 13353

    Suspended

  • Vivantes Humboldt-Klinikum

    Berlin, 13509

    Withdrawn

  • University Hospital of Cologne

    Cologne, 50937

    Withdrawn

  • Carl-Thiem-Klinikum Cottbus

    Cottbus, 03058

    Completed

  • Klinikum Dortmund

    Dortmund, 44137

    Completed

  • Elisabeth Hospital Essen

    Essen, 45138

    Completed

  • Universitätsklinikum Frankfurt

    Frankfurt, 60590

    Withdrawn

  • University Medical Center Hamburg-Eppendorf (UKE)

    Hamburg, 20251

    Suspended

  • Universitätsklinikum Jena

    Jena, 07747

    Suspended

  • University Hospital Leipzig

    Leipzig, 04103

    Suspended

  • Universitätsklinikum Leipzig

    Leipzig, 04103

    Suspended

  • Klinikum rechts der Isar der TU München

    München, 81675

    Suspended

  • Universitätsklinikum Münster

    Münster, 48149

    Suspended

  • Universitäts Klinikum Tübingen

    Tübingen, 72076

    Completed

  • Universitätsklinikum Würzburg

    Würzburg, 97080

    Suspended

Other trials in Germany

United States11 sites, 11 recruiting

  • University of Michigan

    Ann Arbor, Michigan, 48109

    Robert Hyzy, MD

    Recruiting

  • Augusta University

    Augusta, Georgia, 30912

    Jose Vazquez, MD

    Not yet recruiting

  • University of Illinois Health

    Chicago, Illinois, 60612

    Jeffrey Jacobson, MD

    Recruiting

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio, 43210

    Matthew Exline, MD

    Recruiting

  • University of Florida

    Jacksonville, Florida, 32209

    Hadi Hatoum, MD

    Recruiting

  • Tulane Medical Center

    New Orleans, Louisiana, 70112

    Joshua Denson, MD

    Not yet recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065

    Stephen Pastores, MD

    Recruiting

  • University of Pittsburgh Medical Centre

    Pittsburgh, Pennsylvania

    Stephanie Mongomery

    Recruiting

  • Oregon Health and Science University

    Portland, Oregon, 97239-3098

    Akram Khankhana, MD

    Recruiting

  • Brown University - Rhode Island Hospital

    Providence, Rhode Island, 02903

    Mitchell Levy, MD

    Not yet recruiting

  • Wake Forest Baptist Health

    Winston-Salem, North Carolina, 27157-1009

    Ashish Khanna, MD

    Not yet recruiting

Other trials in United States

New Zealand11 sites, 11 recruiting

  • North Shore Hospital

    Auckland, 0620

    Robert Everitt, MD

    Recruiting

  • CVICU, Auckland City Hospital

    Auckland, 1023

    Shay McGuinness, MD

    Recruiting

  • DCCM, Auckland City Hospital

    Auckland, 1023

    Colin McArthur, MD

    Recruiting

  • Middlemore Hospital

    Auckland, 2104

    Tony Williams, MD

    Recruiting

  • Christchurch Hospital

    Christchurch, 8011

    Jay Ritzema-Carter, MD

    Recruiting

  • Waikato Hospital

    Hamilton, 3204

    Robert Martynoga, MD

    Recruiting

  • Taranaki Base Hospital

    New Plymouth, 4310

    Jonathan Albrett, MD

    Recruiting

  • Rotorua Hospital

    Rotorua, 3010

    Ulrike Buehner, MD

    Recruiting

  • Tauranga Hospital

    Tauranga, 3112

    Troy Browne, MD

    Recruiting

  • Wellington Regional Hospital

    Wellington, 6021

    Paul Young, MD

    Recruiting

  • Whangarei Hospital

    Whangarei, 0148

    Ralph Fuchs, MD

    Recruiting

Other trials in New Zealand

Japan10 sites, 10 recruiting

  • St Marianna University School of Medicine

    Kawasaki, Kanagawa, 216-8511

    Recruiting

  • Saiseikai Kumamoto Hospital

    Minami, Kumamoto, 861-4193

    Recruiting

  • Osaka City General Hospital

    Osaka, 534-0021

    Recruiting

  • Nerima Hikarigaoka Hospital

    Tokyo, 130-8575

    Recruiting

  • Tokyo Metropolitan Bokutoh Hospital

    Tokyo, 130-8575

    Recruiting

  • Itabashi Chuo Medical Center

    Tokyo, 174-0051

    Recruiting

  • Tokyo bay Urayasu-Ichikawa Medical Center

    Tokyo, 279-0001

    Recruiting

  • Wakayama Medical University

    Wakayama, 641-8509

    Recruiting

  • Yokohama City University Hospital

    Yokohama, Kanagawa, 236-0004

    Recruiting

  • St. Marianna University Yokohama City Seibu Hospital

    Yokohama, Kanagawa, 241-0811

    Recruiting

Other trials in Japan

Spain10 sites, 10 recruiting

  • Hospital del Mar

    Barcelona

    Rosana Munoz-Bermúdez, M.D.

    Recruiting

  • Hospital Universitario de Jerez

    Cadiz, 11407

    Ángel Estella, MD

    Recruiting

  • Reina Sofia University Hospital

    Córdoba, 14004

    Eduardo Aguilar Alonso, M.D.

    Recruiting

  • Ramon y Cajal University Hospital

    Madrid, 28034

    Cruz Soriano, MD

    Recruiting

  • Hospital Regional de Málaga

    Málaga, 29010

    Manuel Herrera Gutiérrez, MD

    Recruiting

  • Hospital Universitario de Ourense

    Ourense, 32005

    Pablo Vidal, MD

    Recruiting

  • Hospital Marqués de Valdecilla

    Santander, 39008

    Borja Suberviola, MD

    Recruiting

  • Hospital Verge de la Cinta

    Tortosa, 43500

    Ferran Roche Campo, MD

    Recruiting

  • Doctor Peset University Hospital

    Valencia, 46017

    Rafael Zaragoza, MD

    Recruiting

  • Hospital La Fe

    Valencia, 46026

    Paula Ramírez, MD

    Recruiting

Other trials in Spain

Italy8 sites, 8 recruiting

  • AO Spedali Civili di Brescia

    Brescia, 25123

    Simone Piva, MD

    Recruiting

  • Humanitas Research Hospital

    Milan, 20089

    Maurizio Cecconi, MD

    Recruiting

  • Ca' Granda Ospedale Maggiore Policlinico

    Milan, 20122

    Francesco Blasi, MD

    Recruiting

  • IRCCS Ospedale San Raffaele

    Milan, 20132

    Giovanni Landoni, MD

    Recruiting

  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone

    Palermo, 90127

    Andrea Cortegiani, MD

    Recruiting

  • Istituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione

    Palermo, 90127

    Gennaro Martucci, MD

    Recruiting

  • Arcispedale S. Maria Nuova

    Reggio Emilia, 42123

    Elena Mantovani, MD

    Recruiting

  • Ospedale Infermi di Rimini

    Rimini, 47923

    Jonathan Montomoli, MD

    Not yet recruiting

Other trials in Italy

Ireland5 sites, 3 recruiting

  • Cork University Hospital

    Cork, T12 DC4A

    Active, not recruiting

  • Beaumont Hospital

    Dublin

    Ger Curley, Prof.

    Recruiting

  • St. Vincent's University Hospital

    Dublin

    Alistair Nichol, Prof.

    Recruiting

  • University Hospital Galway

    Galway

    John Laffey, M.D.

    Recruiting

  • University Hospital Waterford

    Waterford, X91 ER8E

    Active, not recruiting

Other trials in Ireland

Pakistan5 sites, 5 recruiting

  • Ziauddin University Hospital Clifton Campus

    Karachi, Sindh, 75000

    Madiha Hashmi, MD

    Recruiting

  • Abbasi Shaheed Hospital

    Karachi, Sindh, 75300

    Aneela Kidwai, MD

    Recruiting

  • National Institute of Cardiovascular Diseases, Karachi

    Karachi, Sindh, 75510

    Nawal Salahuddin, MD

    Recruiting

  • South City Hospital, Karachi

    Karachi, Sindh, 75600

    Nasir Khoso, MD

    Recruiting

  • Ziauddin University North Nazimabad Campus

    Karachi, Sindh

    Quratul Ain, MD

    Recruiting

Other trials in Pakistan

India4 sites, 2 recruiting

  • Apollo Main Hospital

    Chennai, Tamil Nadu, 600006

    Active, not recruiting

  • Apollo First Med Hospital

    Chennai, Tamil Nadu, 600010

    Meghena Mathew, MD

    Recruiting

  • Apollo Vanagaram Hospital

    Chennai, Tamil Nadu, 600095

    Active, not recruiting

  • Apollo Speciality Hospital - OMR

    Chennai, Tamil Nadu, 600096

    Deva Jayakumar, MD

    Recruiting

Other trials in India

Nepal4 sites, 4 recruiting

  • Chitwan Medical College

    Bharatpur, 44200

    Basanta Gauli, MD

    Recruiting

  • Grande International Hospital

    Kathmandu, 44600

    Sushil Khanal, MD

    Recruiting

  • Hospital for Advanced Medicine and Surgery (HAMS)

    Kathmandu, 44600

    Hem Paneru, MD

    Recruiting

  • Nepal Mediciti

    Kathmandu, 44600

    Diptesh Aryal, MD

    Recruiting

Other trials in Nepal

Belgium3 sites, 3 recruiting

  • CHU de Charleroi - Hôpital Civil Marie Curie

    Charleroi, 6042

    Patrick Biston, MD

    Recruiting

  • Universitair Ziekenhuis Gent

    Ghent, 9000

    Pieter Depuydt, Prof.

    Recruiting

  • CHU Namur site Godinne

    Namur, 5530

    Pierre Bulpa, MD

    Recruiting

Other trials in Belgium

Croatia3 sites, 2 recruiting

  • General County Hospital Požega

    Požega, 34000

    Zdravko Andrić, MD

    Recruiting

  • University Hospital Centre Zagreb

    Zagreb, 10000

    Ana Vujaklija Brajković, MD

    Recruiting

  • University Hospital for Infectious Diseases

    Zagreb, 10000

    Withdrawn

Other trials in Croatia

Israel3 sites

  • Rambam Medical Center

    Haifa, 3109601

    Withdrawn

  • Beilinson Hospital, Rabin Medical Center

    Petah Tikva, 4941492

    Suspended

  • The Baruch Padeh Medical Center

    Poria – Neve Oved, 1528001

    Withdrawn

Other trials in Israel

Portugal3 sites, 1 recruiting

  • Centro Hospitalar do Medio Tejo

    Abrantes

    Nuno Catorze, M.D.

    Recruiting

  • Hospital Ocidental

    Lisbon, 1169-050

    Suspended

  • Hospital Lusíadas Lisbon

    Lisbon

    Suspended

Other trials in Portugal

Serbia3 sites, 1 recruiting

  • University Clinical Centre of Serbia

    Belgrade, 11000

    Suspended

  • University Hospital Center Dr Dragiša Mišović

    Belgrade, 11000

    Suspended

  • Clinical Centre of Niš

    Niš, 18000

    Tanja Pejčić, MD

    Recruiting

Other trials in Serbia

Czechia2 sites, 1 recruiting

  • Fakultní nemocnice Královské Vinohrady

    Prague, 10000

    František Duška, MD

    Recruiting

  • Teplice Hospital

    Teplice, 41501

    Suspended

Other trials in Czechia

Finland2 sites

  • Helsinki University Hospital

    Helsinki, 00290

    Suspended

  • Tampere University Hospital

    Tampere, 33520

    Suspended

Other trials in Finland

Hungary2 sites

  • Jósa András County Hospital

    Nyíregyháza, 4400

    Completed

  • Almási Balogh Pál Kórház

    Ózd, 3600

    Completed

Other trials in Hungary

Slovenia2 sites, 1 recruiting

  • University Clinic of Respiratory and Allergic Diseases Golnik

    Golnik, 4204

    Suspended

  • University Medical Centre Maribor

    Maribor, 2000

    Andre Markota, MD

    Recruiting

Other trials in Slovenia

Colombia1 site, 1 recruiting

  • Universidad de La Sabana

    Chía, Cundinamarca

    Recruiting

Other trials in Colombia

Estonia1 site

  • Tartu University Hospital

    Tartu, 50406

    Suspended

Other trials in Estonia

Romania1 site

  • Clinical Hospital of Infectious and Tropical Diseases "Dr. Victor Babes"

    Bucharest, 030303

    Suspended

Other trials in Romania

Saudi Arabia1 site, 1 recruiting

  • King Abdulaziz Medical City

    Riyadh, 14611

    Yaseen Arabi, MD

    Recruiting

Other trials in Saudi Arabia

Switzerland1 site

  • University Hospital Zürich

    Zurich, 8091

    Suspended

Other trials in Switzerland

About this study

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.

The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia.

In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19.

REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.

Read the detailed description

Community-acquired pneumonia (CAP) that is of sufficient severity to require admission to an intensive care unit (ICU) is associated with substantial mortality.

Patients with pneumonia who are being treated in an ICU will receive therapy that consists of many different treatments, as many as 20 or 30. These treatments act together to treat both the infection and its effects on the body. When treating a patient, doctors choose from many different treatments, most of which are known or believed to be safe and effective. However, doctors don't always know which treatment option is the better one, as individuals or groups of individuals may respond differently. This study aims to help doctors understand which treatments work best.

This clinical study has been designed in a way that allows the information from patients already in the study to help new patients joining the study. Most studies aren't able to do that. REMAP-CAP has been designed to:

  • Evaluate multiple treatment strategies, at the same time, in the same patient.
  • Reach platform conclusions when sufficient data is accrued, rather than when a pre-specified sample size is reached
  • Utilise data that is already accrued to increase the likelihood that patients within the trial are randomised to treatments that are more likely to be beneficial
  • New questions can be substituted into the trial as initial questions are answered, meaning that the trial can be perpetual or open-ended
  • Interactions between interventions in different domains can be evaluated

It is reasonable to presume that any pandemic respiratory infection of major significance to public health will manifest as life-threatening respiratory infection including Severe Acute Respiratory illness and severe Community Acquired Pneumonia (CAP) with concomitant admission to hospital, and for some patients, admission to an Intensive Care Unit (ICU). Previous pandemics and more localized outbreaks of respiratory emerging infections have resulted in severe CAP and ICU admission.

Previous pandemics and outbreaks of emerging infectious diseases have outlined the urgent need for evidence, preferably from Randomized Controlled Trials (RCTs), to guide best treatment. However, there are substantial challenges associated with being able to organize such trials when the time of onset of a pandemic and its exact nature are unpredictable. As an adaptive platform trial that enrolls patients during the interpandemic period, REMAP-CAP is ideally positioned to adapt, in the event of a respiratory pandemic, to evaluate existing treatments as well as novel approaches.

Being tested
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate
Keywords
Pneumonia, Lung Diseases, Respiratory Tract Diseases, Respiratory Tract Infections, Anti-Bacterial Agents, Moxifloxacin, Levofloxacin, Antibiotics, Hydrocortisone, Anti-Infective Agents, Ceftriaxone, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Oseltamivir, COVID-19, Influenza, Intensive care, Critical care, SARS-CoV-2
Medical subject headings
Community-Acquired Pneumonia, Influenza, Human, COVID-19, Pneumonia, Lung Diseases, Respiratory Tract Diseases, Respiratory Tract Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CeftriaxoneDrug

    The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

  • Moxifloxacin or LevofloxacinDrug

    The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

  • Piperacillin-tazobactamDrug

    The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

  • CeftarolineDrug

    The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

    Note: this intervention is now closed.

  • Amoxicillin-clavulanateDrug

    The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

  • Standard course macrolideDrug

    Standard course of macrolide therapy, discontinued between study day 3 and the end of study day 5.

    The dosing of and route of administration is not protocolised, the following guidance is provided:

    • Initial IV administration of a macrolide is strongly preferred
    • The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.
    • The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.

  • Extended course macrolideDrug

    Extended course of macrolide therapy discontinued at the end of study day 14 or hospital discharge (whichever occurs first).

    The dosing of and route of administration is not protocolised, the following guidance is provided:

    • Initial IV administration of a macrolide is strongly preferred
    • The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.
    • The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.

  • No systemic corticosteroidOther

    Patients are not to receive any systemic corticosteroids, including hydrocortisone, to study day 28 or hospital discharge (whichever occurs first).

  • Fixed-duration HydrocortisoneDrug

    50mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.

    Note: this intervention is now closed.

  • Shock-dependent hydrocortisoneDrug

    50mg IV hydrocortisone every 6 hours while the patient is in septic shock

  • Fixed-duration higher dose HydrocortisoneDrug

    100mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.

    Note: this intervention was only available to patients with suspected or proven COVID-19 and is now closed.

  • No antiviral agent for influenzaOther

    No antiviral agent intended to be active against influenza infection is to be administered

  • Five-days oseltamivirDrug

    Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first)

  • Ten-days oseltamivirDrug

    Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first)

  • No antiviral agent for COVID-19Other

    No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered

  • Lopinavir / RitonavirDrug

    Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.

    Note: this intervention is now closed.

  • HydroxychloroquineDrug

    Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).

    Note: this intervention is now closed.

  • Hydroxychloroquine + lopinavir/ritonavirDrug

    Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.

    Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).

    Note: this intervention is now closed.

  • IvermectinDrug

    Ivermectin administered enterally at a dose of 0.2 mg/kg once daily with a maximum daily dose of 24mg/day.

    Note: this intervention is now closed.

  • No immune modulation for COVID-19Other

    No immune modulating agent intended to be active against COVID-19 is to be administered.

    Note: this intervention is now closed.

  • Interferon beta-1aDrug

    Also called IFN-β1a

    IFN-β1a 10 μg will be administered as an intravenous bolus injection via a central or peripheral line. IFN-β1a will be administered once daily for 6 days or until ICU discharge, whichever occurs first.

    Note: this intervention is now closed.

  • AnakinraDrug

    A loading dose of 300mg anakinra will be administered as a bolus via central or peripheral line. This is followed by maintenance doses of 100mg of anakinra administered every 6 hours.

    In patients with renal impairment, anakinra will be administered on alternate days.

    Note: this intervention is now closed.

  • TocilizumabDrug

    Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg.

    Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.

    Note: this intervention is now closed.

  • SarilumabDrug

    Sarilumab will be administered as a single dose of 400mg, via IV infusion through peripheral or central line over a one-hour period.

    Note: this intervention is now closed.

  • Local standard venous thromboprophylaxisDrug

    Standard venous thromboprophylaxis that complies with local guidelines or usual practice will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first.

    Note: this intervention is now closed.

  • Therapeutic dose anticoagulationDrug

    Patients will be administered either low molecular weight heparin (LMWH) or unfractionated heparin (UFH) to achieve systemic anticoagulation. Either agent may be used and the same patient may be switched between UFH and LMWH at the discretion of the treating clinician.

    Note: this intervention is now closed.

  • Conventional low dose thromboprophylaxisDrug

    Low dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.

  • Intermediate dose thromboprophylaxisDrug

    Intermediate dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.

  • Continuation of therapeutic dose anticoagulationDrug

    Patients already receiving therapeutic dose anticoagulation at the time of randomisation to this intervention will be administered either unfractionated heparin by IV infusion or low-molecular weight heparin to achieve systemic anticoagulation according to local practice for acute VTE treatment for 14 days following randomisation or until hospital discharge, whichever occurs first.

    Note: this intervention is now closed.

  • No immunoglobulinOther

    No immunoglobulin intended to be active against SARS-CoV-2 infection is to be administered.

  • Convalescent plasmaBiological

    Patients will receive at least one and no more than two units of ABO compatible convalescent plasma within 48 hours of randomisation.

  • Delayed administration of convalescent plasmaBiological

    Note: this intervention is now closed.

  • No vitamin COther

    No high dose intravenous vitamin C is to be administered

    Note: this intervention is now closed.

  • Vitamin CDrug

    Intravenous Vitamin C 50mg/kg administered every 6 hours for 16 doses

    Note: this intervention is now closed.

  • No antiplateletOther

    No antiplatelet agent or NSAID to be administered.

    Note: this intervention is now closed.

  • AspirinDrug

    Also called acetylsalicylic acid

    Aspirin administered at either 75mg or 100mg once per day for 14 days or until hospital discharge, whichever occurs first.

    Note: this intervention is now closed.

  • P2Y12 inhibitorDrug

    Also called Clopidogrel, Prasugrel, Ticagrelor

    Site-selected P2Y12 inhibitor:

    • Clopidogrel: administered 75 mg once per day for 14 days or until hospital discharge, whichever occurs first.
    • Prasugrel: If patient is aged less than 75 years and measured or estimated weight if 60kg or more, and initial loading dose of prasugrel 60 mg will be administered, followed by maintenance dose of 10 mg per day.
    • Ticagrelor: administered enterally at 60mg twice daily for 14 days or until hospital discharge, whichever occurs first.

    Note: this intervention is now closed.

  • No simvastatinOther

    No simvastatin intended to be active against COVID-19 is to be administered

    Note: this intervention is now closed.

  • SimvastatinDrug

    Simvastatin 80mg administered once daily via enteral route, while the patient remains in hospital up to 28 days after randomisation

    Note: this intervention is now closed.

  • EritoranDrug

    Eritoran initiated with a 26.24 mg loading dose (6.56 mg/h IV for 4 hours), followed by a second 13.12 mg loading dose (6.56 mg/h IV for 2 hours) at 12 hours after initiation. Patients will then receive twenty-six 6.56 mg maintenance doses (3.28 mg/h IV for 2 hours) every 12 hours thereafter (total of 14 days). Dosing will be stopped if the patient is discharged from hospital

    Note: this intervention is now closed.

  • ApremilastDrug

    Apremilast administered 30mg twice daily for 14 days or until hospital discharge, whichever occurs first.

    Note: this intervention is now closed.

  • Clinician-preferred mechanical ventilation strategyProcedure or surgery

    Clinician-preferred ventilation strategy, including mode of ventilation and all ventilatory parameters

  • Protocolised mechanical ventilation strategyProcedure or surgery

    Invasive mechanical ventilation strategy delivered as outlined in relevant protocol documents for this domain.

  • No renin-angiotensin system inhibitorOther

    No RAS inhibitor (i.e. no ACEi or ARB) is to be administered up to the end of study day 10.

    Note: this intervention is now closed.

  • Angiotensin converting enzyme inhibitorDrug

    Also called Ramipril, Lisinopril, Perindopril, Enalapril

    Site-preferred ACEi agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.

    Note: this intervention is now closed.

  • Angiotensin Receptor BlockersDrug

    Also called Losartan, Valsartan, Candesartan, Irbesartan

    Site-preferred ARB agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.

    Note: this intervention is now closed.

  • ARB + DMX-200Drug

    Site-preferred ARB agent administered in combination with DMX-200 for 10 days or until hospital discharge, whichever occurs first.

    ARB administered as directed by the treating clinician. DMX-200 administered enterally at a dose of 120mg twice daily.

    Note: this intervention is now closed.

  • No cysteamineOther

    No cysteamine to be administered until the end of study day 10 or hospital discharge, whichever occurs first.

    Note: this intervention is now closed.

  • CysteamineDrug

    Cysteamine administered every 8 hours at a dose of 5 mg/kg estimated or measured body weight (maximum dose of 500mg), for ten days or until ICU discharge, whichever occurs first.

    Note: this intervention is now closed.

  • Fixed-duration dexamethasoneDrug

    6 mg of IV or enteral dexamethasone will be administered daily for up to 10 days while in hospital.

  • Baloxavir MarboxilDrug

    Baloxavir marboxil administered on days 1 and 4 post-randomisation.

  • Five-days oseltamivir + baloxavir marboxilDrug

    Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.

  • Ten-days oseltamivir + baloxavir marboxilDrug

    Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.

  • No endothelial modulatorOther

    No endothelial modulator (imatinib or another tyrosine kinase inhibitor targeting the same pathway as imatinib) is to be administered.

  • ImatinibDrug

    Enteral imatinib will be administered as a single 800mg loading dose (study day 1) followed by 400mg daily until study day 14 or discharge.

  • No Immune Modulator for InfluenzaOther

    No immune modulating agent intended to be active against influenza is to be administered.

  • TocilizumabDrug

    Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg. In children weighing less than 30kg, tocilizumab dose will be 12mg/kg.

    Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.

  • BaricitinibDrug

    Baricitinib will be administered at a dose that is determined by age and renal function, for up to 10 days or hospital discharge (whichever occurs first).

  • No antiviral agent for COVID-19Other

    No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered

  • Nirmatrelvir/ritonavirDrug

    Also called Paxlovid

    Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days.

  • RemdesivirDrug

    Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.

  • Nirmatrelvir/ritonavir + remdesivirDrug

    Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days. Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.

Study groups in NCT02735707
Study groupRoleWhat they receive
Antibiotic DomainOtherPatients with community-acquired pneumonia admitted to participating intensive care units and requiring empiric antibiotic therapy will be randomised one of five antibiotic interventions. Note: the ceftaroline + macrolide intervention has been closed to recruitment.
Receives: Drug: Ceftriaxone; Drug: Moxifloxacin or Levofloxacin; Drug: Piperacillin-tazobactam; Drug: Ceftaroline; Drug: Amoxicillin-clavulanate
Macrolide Duration DomainOtherPatients with community-acquired pneumonia admitted to participating intensive care units who have been allocated to a beta-lactam antibiotic intervention in the Antibiotic Domain will be randomised to either a standard course or extended course of macrolide therapy
Receives: Drug: Standard course macrolide; Drug: Extended course macrolide
Corticosteroid DomainOtherPatients with community acquired pneumonia (CAP) admitted to participating hospitals will be randomised to a steroid use strategy. Note: this domain is now closed to patients with suspected or proven COVID-19. It remains open to patients with CAP without COVID-19. Note: the fixed-course hydrocortisone has been closed to recruitment
Receives: Other: No systemic corticosteroid; Drug: Fixed-duration Hydrocortisone; Drug: Shock-dependent hydrocortisone; Drug: Fixed-duration higher dose Hydrocortisone; Drug: Fixed-duration dexamethasone
Influenza Antiviral DomainOtherPatients with community-acquired pneumonia admitted to participating hospitals with microbiological testing confirmed influenza infection will be randomised to one of six interventions.
Receives: Other: No antiviral agent for influenza; Drug: Five-days oseltamivir; Drug: Ten-days oseltamivir; Drug: Baloxavir Marboxil; Drug: Five-days oseltamivir + baloxavir marboxil; Drug: Ten-days oseltamivir + baloxavir marboxil
COVID-19 Antiviral DomainOtherPatients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to no ivermectin or ivermectin. Note: an earlier version of this domain evaluated lopinavir-ritonavir, hydroxychloroquine, and combination lopinavir-ritonavir and hydroxychloroquine against a 'no antiviral' control. This domain is now closed.
Receives: Other: No antiviral agent for COVID-19; Drug: Lopinavir / Ritonavir; Drug: Hydroxychloroquine; Drug: Hydroxychloroquine + lopinavir/ritonavir; Drug: Ivermectin
COVID-19 Immune Modulation DomainOtherPatients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to one of up to five interventions. Note: this domain is now closed.
Receives: Other: No immune modulation for COVID-19; Drug: Interferon beta-1a; Drug: Anakinra; Drug: Tocilizumab; Drug: Sarilumab
Anticoagulation DomainOtherPatients admitted to participating intensive care units with suspected or microbiological testing confirmed COVID-19 will be randomised to an anticoagulation strategy. Note: A previous version of this domain evaluated local standard venous thromboprophylaxis against therapeutic dose anticoagulation. This domain is now closed.
Receives: Drug: Local standard venous thromboprophylaxis; Drug: Therapeutic dose anticoagulation; Drug: Conventional low dose thromboprophylaxis; Drug: Intermediate dose thromboprophylaxis; Drug: Continuation of therapeutic dose anticoagulation
Immunoglobulin DomainOtherImmunosuppressed patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to receive no immunoglobulin for COVID-19, or to receive high-titre convalescent plasma. Note: an earlier version of this domain was not restricted to immunosuppressed patients.
Receives: Other: No immunoglobulin; Biological: Convalescent plasma; Biological: Delayed administration of convalescent plasma
Vitamin C DomainOtherPatients admitted to participating hospitals with community-acquired pneumonia will be randomised to receive no vitamin C, or vitamin C. Note: this domain is now closed.
Receives: Other: No vitamin C; Drug: Vitamin C
Simvastatin DomainOtherPatients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to receive no simvastatin, or simvastatin. Note: this domain is now closed.
Receives: Other: No simvastatin; Drug: Simvastatin
Antiplatelet DomainOtherPatients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to receive no antiplatelet, aspirin, or site-preferred P2Y12 inhibitor. Note: this domain is now closed.
Receives: Other: No antiplatelet; Drug: Aspirin; Drug: P2Y12 inhibitor
Mechanical Ventilation DomainOtherPatients with community-acquired pneumonia admitted to participating intensive care units who are intubated and receiving invasive mechanical ventilation will be randomised to protocolised mechanical ventilation strategy, or clinician-preferred mechanical ventilation strategy
Receives: Procedure: Clinician-preferred mechanical ventilation strategy; Procedure: Protocolised mechanical ventilation strategy
COVID-19 Immune Modulation (2) DomainOtherPatients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to receive one of three interventions. Note: this domain is now closed.
Receives: Other: No immune modulation for COVID-19; Drug: Eritoran; Drug: Apremilast
ACE2 RAS DomainOtherPatients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to one of up to five renin-angiotensin system blockade strategies. Note: this domain is now closed.
Receives: Other: No renin-angiotensin system inhibitor; Drug: Angiotensin converting enzyme inhibitor; Drug: Angiotensin Receptor Blockers; Drug: ARB + DMX-200
Cysteamine DomainOtherPatients admitted to participating hospitals with severe community-acquired pneumonia, including patients with suspected or proven influenza or COVID-19, will be randomised to receive no cysteamine, or cysteamine. Note: this domain is now closed.
Receives: Other: No cysteamine; Drug: Cysteamine
Endothelial DomainOtherPatients admitted to participating hospitals with severe community-acquired pneumonia, including patients with suspected or proven influenza or COVID-19, will be randomised to receive no endothelial modulator or enteral imatinib.
Receives: Other: No endothelial modulator; Drug: Imatinib
Influenza Immune ModulationOtherPatients with community-acquired pneumonia admitted to participating intensive care units with microbiological testing confirmed influenza infection will be randomised to one of three interventions.
Receives: Other: No Immune Modulator for Influenza; Drug: Tocilizumab; Drug: Baricitinib
COVID-19 Antiviral (II) DomainOtherPatients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to one of up to four interventions.
Receives: Other: No antiviral agent for COVID-19; Drug: Nirmatrelvir/ritonavir; Drug: Remdesivir; Drug: Nirmatrelvir/ritonavir + remdesivir

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. All-cause mortality

    Measured: Day 90

  2. Days alive and not receiving organ support in ICU

    Primary end-point for patients with suspected or proven COVID-19 pandemic infection

    Measured: Day 21

Secondary outcomes (11)

  1. ICU Mortality

    Measured: Day 90

  2. ICU length of stay

    Measured: Day 90

  3. Hospital length of stay

    Measured: Day 90

  4. Ventilator free days

    Measured: Day 28

  5. Organ failure free days

    Measured: Day 28

  6. All-cause mortality

    Measured: 6 months

  7. Health-related Quality of life assessment

    EQ5D-5L and WHODAS 2.0 (not completed in all regions)

    Measured: 6 months

  8. Proportion of intubated patients who receive a tracheostomy

    Measured: Day 28

  9. Destination at time of hospital discharge

    Characterised as home, rehabilitation hospital, nursing home or long-term care facility, or another acute hospital

    Measured: Free text Day 90

  10. Readmission to the index ICU during the index hospitalization

    Measured: Day 90

  11. World Health Organisation 8-point ordinal scale outcome

    Measured: Hospital discharge

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Apr 2016 (estimated)
  2. Study start11 Apr 2016
  3. Primary completionFeb 2026 (estimated)
  4. Study completionFeb 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Factorial
Model description
Adaptive Bayesian Platform Trial evaluating multiple interventions in multiple domains
Masking
None (open label)
Enrolment
20,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02735707
Sponsor's protocol ID
U1111-1189-1653
Other IDs
2015-002340-14, 602525, 16/631, APP1101719, 158584, 2023-507889-89-00, 965313, 2023
Acronym
REMAP-CAP
Status last verified
Jul 2024
First submitted
11 Dec 2015
Last updated
12 Jul 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes

Publications

  • Boyle AJ, Ryan EG, Berry LR, Berry S, Derde L, Lawler PR, Lorenzi E, O'Kane CM, Shankar-Hari M, Veerdonk FV, Gordon AC, McAuley DF; REMAP-CAP Immune Modulation Domain Investigators. Evaluating plasma ferritin and suPAR as treatable traits for critically ill patients with COVID-19 treated with anakinra: an exploratory analysis of the immune modulation domain of the REMAP-CAP randomised clinical trial. Crit Care. 2026 Oct 1;30(1):506. doi: 10.1186/s13054-026-06311-3.

    PubMed 42823695

  • Derde L, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, Annane D, Beane A, Beasley R, Bonten MJM, Bradbury CA, Brunkhorst FM, Buzgau A, Buxton M, Cheng AC, Cooper N, Cove M, Cremer OL, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Galea J, Goossens H, Haniffa R, Hills TE, Huang DT, Ichihara N, King A, Lamontagne F, Lawler PR, Leavis HL, Lewis RJ, Litton E, Marshall JC, Mayr FB, McAuley DF, McGlothlin A, McGuinness SP, McVerry BJ, Morpeth SC, Murthy S, Netea MG, Ogungbenro K, Orr K, Parke RL, Parker JC, Patanwala AE, Pettila V, Reyes LF, Saito H, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Sligl WI, Turgeon AF, Turner AM, Tong SYC, Vaara S, Youngstein T, Zarychanski R, Green C, Higgins AM, McArthur CJ, Berry LR, Lorenzi E, Berry S, Webb SA, Angus DC, van de Veerdonk FL. Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial. Thorax. 2025 Jul 15;80(8):530-539. doi: 10.1136/thorax-2024-222488.

    PubMed 40360262

  • REMAP-CAP Investigators; Angus DC. Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia : The REMAP-CAP Corticosteroid Domain Randomized Clinical Trial. Intensive Care Med. 2025 Apr;51(4):665-680. doi: 10.1007/s00134-025-07861-w. Epub 2025 Apr 22.

    PubMed 40261382

  • REMAP-CAP Investigators; Hills TE, Lorenzi E, Berry LR, Shyamsundar M, Al-Beidh F, Annane D, Arabi Y, Aryal D, Au C, Beane A, Bhimani Z, Bonten M, Bradbury CA, Brunkhorst FM, Burrell A, Buxton M, Calfee CS, Cecconi M, Cheng AC, Cove ME, Detry MA, Estcourt LJ, Fitzgerald M, Goligher EC, Goossens H, Green C, Haniffa R, Harrison DA, Hashmi M, Higgins AM, Horvat C, Huang DT, Ichihara N, Jayakumar D, Kruger PS, Lamontagne F, Lampro L, Lawler PR, Marshall JC, Mason AJ, McGlothlin A, McGuinness S, McQuilten ZK, McVerry BJ, Mouncey PR, Murthy S, Neal MD, Nichol AD, O'Kane CM, Parke RL, Parker JC, Rabindrarajan E, Reyes LF, Rowan KM, Saito H, Santos M, Saunders CT, Seymour CW, Shankar-Hari M, Sinha P, Thompson BT, Turgeon AF, Turner AM, van de Veerdonk F, Weis S, Young IS, Zarychanski R, Lewis RJ, McArthur CJ, Angus DC, Berry SM, Derde LPG, Webb SA, Gordon AC, McAuley DF. Simvastatin in Critically Ill Patients with Covid-19. N Engl J Med. 2023 Dec 21;389(25):2341-2354. doi: 10.1056/NEJMoa2309995. Epub 2023 Oct 25.

    PubMed 37888913

  • LOVIT-COVID Investigators, on behalf of the Canadian Critical Care Trials Group, and the REMAP-CAP Investigators; Adhikari NKJ, Hashmi M, Tirupakuzhi Vijayaraghavan BK, Haniffa R, Beane A, Webb SA, Angus DC, Gordon AC, Cook DJ, Guyatt GH, Berry LR, Lorenzi E, Mouncey PR, Au C, Pinto R, Menard J, Sprague S, Masse MH, Huang DT, Heyland DK, Nichol AD, McArthur CJ, de Man A, Al-Beidh F, Annane D, Anstey M, Arabi YM, Battista MC, Berry S, Bhimani Z, Bonten MJM, Bradbury CA, Brant EB, Brunkhorst FM, Burrell A, Buxton M, Cecconi M, Cheng AC, Cohen D, Cove ME, Day AG, Derde LPG, Detry MA, Estcourt LJ, Fagbodun EO, Fitzgerald M, Goossens H, Green C, Higgins AM, Hills TE, Horvat C, Ichihara N, Jayakumar D, Kanji S, Khoso MN, Lawler PR, Lewis RJ, Litton E, Marshall JC, McAuley DF, McGlothlin A, McGuinness SP, McQuilten ZK, McVerry BJ, Murthy S, Parke RL, Parker JC, Reyes LF, Rowan KM, Saito H, Salahuddin N, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Tolppa T, Trapani T, Turgeon AF, Turner AM, Udy AA, van de Veerdonk FL, Zarychanski R, Lamontagne F. Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials. JAMA. 2023 Nov 14;330(18):1745-1759. doi: 10.1001/jama.2023.21407.

    PubMed 37877585

  • Fischer AL, Messer S, Riera R, Martimbianco ALC, Stegemann M, Estcourt LJ, Weibel S, Monsef I, Andreas M, Pacheco RL, Skoetz N. Antiplatelet agents for the treatment of adults with COVID-19. Cochrane Database Syst Rev. 2023 Jul 25;7(7):CD015078. doi: 10.1002/14651858.CD015078.

    PubMed 37489818

  • Writing Committee for the REMAP-CAP Investigators; Lawler PR, Derde LPG, van de Veerdonk FL, McVerry BJ, Huang DT, Berry LR, Lorenzi E, van Kimmenade R, Gommans F, Vaduganathan M, Leaf DE, Baron RM, Kim EY, Frankfurter C, Epelman S, Kwan Y, Grieve R, O'Neill S, Sadique Z, Puskarich M, Marshall JC, Higgins AM, Mouncey PR, Rowan KM, Al-Beidh F, Annane D, Arabi YM, Au C, Beane A, van Bentum-Puijk W, Bonten MJM, Bradbury CA, Brunkhorst FM, Burrell A, Buzgau A, Buxton M, Cecconi M, Cheng AC, Cove M, Detry MA, Estcourt LJ, Ezekowitz J, Fitzgerald M, Gattas D, Godoy LC, Goossens H, Haniffa R, Harrison DA, Hills T, Horvat CM, Ichihara N, Lamontagne F, Linstrum KM, McAuley DF, McGlothlin A, McGuinness SP, McQuilten Z, Murthy S, Nichol AD, Owen DRJ, Parke RL, Parker JC, Pollock KM, Reyes LF, Saito H, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Singh V, Turgeon AF, Turner AM, Zarychanski R, Green C, Lewis RJ, Angus DC, Berry S, Gordon AC, McArthur CJ, Webb SA. Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial. JAMA. 2023 Apr 11;329(14):1183-1196. doi: 10.1001/jama.2023.4480.

    PubMed 37039790

  • Nurmi V, Knight C, Estcourt L, Hepojoki J, Lamikanra AA, Tsang HP, Roberts DJ, Polack FP, Simmonds P, Hedman K, Alvarez-Paggi D, Harvala H. The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors. J Infect Dis. 2023 Aug 11;228(3):245-250. doi: 10.1093/infdis/jiad070.

    PubMed 36967714

  • Goligher EC, Lawler PR, Jensen TP, Talisa V, Berry LR, Lorenzi E, McVerry BJ, Chang CH, Leifer E, Bradbury C, Berger J, Hunt BJ, Castellucci LA, Kornblith LZ, Gordon AC, McArthur C, Webb S, Hochman J, Neal MD, Zarychanski R, Berry S, Angus DC; REMAP-CAP, ATTACC, and ACTIV-4a Investigators. Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19. JAMA. 2023 Apr 4;329(13):1066-1077. doi: 10.1001/jama.2023.3651.

    PubMed 36942550

  • REMAP-CAP Writing Committee for the REMAP-CAP Investigators; Bradbury CA, Lawler PR, Stanworth SJ, McVerry BJ, McQuilten Z, Higgins AM, Mouncey PR, Al-Beidh F, Rowan KM, Berry LR, Lorenzi E, Zarychanski R, Arabi YM, Annane D, Beane A, van Bentum-Puijk W, Bhimani Z, Bihari S, Bonten MJM, Brunkhorst FM, Buzgau A, Buxton M, Carrier M, Cheng AC, Cove M, Detry MA, Estcourt LJ, Fitzgerald M, Girard TD, Goligher EC, Goossens H, Haniffa R, Hills T, Huang DT, Horvat CM, Hunt BJ, Ichihara N, Lamontagne F, Leavis HL, Linstrum KM, Litton E, Marshall JC, McAuley DF, McGlothlin A, McGuinness SP, Middeldorp S, Montgomery SK, Morpeth SC, Murthy S, Neal MD, Nichol AD, Parke RL, Parker JC, Reyes LF, Saito H, Santos MS, Saunders CT, Serpa-Neto A, Seymour CW, Shankar-Hari M, Singh V, Tolppa T, Turgeon AF, Turner AM, van de Veerdonk FL, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Derde LPG, Webb SA, Gordon AC. Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2022 Apr 5;327(13):1247-1259. doi: 10.1001/jama.2022.2910.

    PubMed 35315874

  • Writing Committee for the REMAP-CAP Investigators; Estcourt LJ, Turgeon AF, McQuilten ZK, McVerry BJ, Al-Beidh F, Annane D, Arabi YM, Arnold DM, Beane A, Begin P, van Bentum-Puijk W, Berry LR, Bhimani Z, Birchall JE, Bonten MJM, Bradbury CA, Brunkhorst FM, Buxton M, Callum JL, Chasse M, Cheng AC, Cove ME, Daly J, Derde L, Detry MA, De Jong M, Evans A, Fergusson DA, Fish M, Fitzgerald M, Foley C, Goossens H, Gordon AC, Gosbell IB, Green C, Haniffa R, Harvala H, Higgins AM, Hills TE, Hoad VC, Horvat C, Huang DT, Hudson CL, Ichihara N, Laing E, Lamikanra AA, Lamontagne F, Lawler PR, Linstrum K, Litton E, Lorenzi E, MacLennan S, Marshall J, McAuley DF, McDyer JF, McGlothlin A, McGuinness S, Miflin G, Montgomery S, Mouncey PR, Murthy S, Nichol A, Parke R, Parker JC, Priddee N, Purcell DFJ, Reyes LF, Richardson P, Robitaille N, Rowan KM, Rynne J, Saito H, Santos M, Saunders CT, Serpa Neto A, Seymour CW, Silversides JA, Tinmouth AA, Triulzi DJ, Turner AM, van de Veerdonk F, Walsh TS, Wood EM, Berry S, Lewis RJ, Menon DK, McArthur C, Zarychanski R, Angus DC, Webb SA, Roberts DJ, Shankar-Hari M. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2021 Nov 2;326(17):1690-1702. doi: 10.1001/jama.2021.18178.

    PubMed 34606578

  • Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.

    PubMed 34473343

  • REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators; Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Turgeon AF, Kornblith LZ, Kahn SR, Marshall JC, Kim KS, Houston BL, Derde LPG, Cushman M, Tritschler T, Angus DC, Godoy LC, McQuilten Z, Kirwan BA, Farkouh ME, Brooks MM, Lewis RJ, Berry LR, Lorenzi E, Gordon AC, Ahuja T, Al-Beidh F, Annane D, Arabi YM, Aryal D, Baumann Kreuziger L, Beane A, Bhimani Z, Bihari S, Billett HH, Bond L, Bonten M, Brunkhorst F, Buxton M, Buzgau A, Castellucci LA, Chekuri S, Chen JT, Cheng AC, Chkhikvadze T, Coiffard B, Contreras A, Costantini TW, de Brouwer S, Detry MA, Duggal A, Dzavik V, Effron MB, Eng HF, Escobedo J, Estcourt LJ, Everett BM, Fergusson DA, Fitzgerald M, Fowler RA, Froess JD, Fu Z, Galanaud JP, Galen BT, Gandotra S, Girard TD, Goodman AL, Goossens H, Green C, Greenstein YY, Gross PL, Haniffa R, Hegde SM, Hendrickson CM, Higgins AM, Hindenburg AA, Hope AA, Horowitz JM, Horvat CM, Huang DT, Hudock K, Hunt BJ, Husain M, Hyzy RC, Jacobson JR, Jayakumar D, Keller NM, Khan A, Kim Y, Kindzelski A, King AJ, Knudson MM, Kornblith AE, Kutcher ME, Laffan MA, Lamontagne F, Le Gal G, Leeper CM, Leifer ES, Lim G, Gallego Lima F, Linstrum K, Litton E, Lopez-Sendon J, Lother SA, Marten N, Saud Marinez A, Martinez M, Mateos Garcia E, Mavromichalis S, McAuley DF, McDonald EG, McGlothlin A, McGuinness SP, Middeldorp S, Montgomery SK, Mouncey PR, Murthy S, Nair GB, Nair R, Nichol AD, Nicolau JC, Nunez-Garcia B, Park JJ, Park PK, Parke RL, Parker JC, Parnia S, Paul JD, Pompilio M, Quigley JG, Rosenson RS, Rost NS, Rowan K, Santos FO, Santos M, Santos MO, Satterwhite L, Saunders CT, Schreiber J, Schutgens REG, Seymour CW, Siegal DM, Silva DG Jr, Singhal AB, Slutsky AS, Solvason D, Stanworth SJ, Turner AM, van Bentum-Puijk W, van de Veerdonk FL, van Diepen S, Vazquez-Grande G, Wahid L, Wareham V, Widmer RJ, Wilson JG, Yuriditsky E, Zhong Y, Berry SM, McArthur CJ, Neal MD, Hochman JS, Webb SA, Zarychanski R. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med. 2021 Aug 26;385(9):777-789. doi: 10.1056/NEJMoa2103417. Epub 2021 Aug 4.

    PubMed 34351722

  • ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators; Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR, Turgeon AF, Escobedo J, Huang DT, Bradbury CA, Houston BL, Kornblith LZ, Kumar A, Kahn SR, Cushman M, McQuilten Z, Slutsky AS, Kim KS, Gordon AC, Kirwan BA, Brooks MM, Higgins AM, Lewis RJ, Lorenzi E, Berry SM, Berry LR, Aday AW, Al-Beidh F, Annane D, Arabi YM, Aryal D, Baumann Kreuziger L, Beane A, Bhimani Z, Bihari S, Billett HH, Bond L, Bonten M, Brunkhorst F, Buxton M, Buzgau A, Castellucci LA, Chekuri S, Chen JT, Cheng AC, Chkhikvadze T, Coiffard B, Costantini TW, de Brouwer S, Derde LPG, Detry MA, Duggal A, Dzavik V, Effron MB, Estcourt LJ, Everett BM, Fergusson DA, Fitzgerald M, Fowler RA, Galanaud JP, Galen BT, Gandotra S, Garcia-Madrona S, Girard TD, Godoy LC, Goodman AL, Goossens H, Green C, Greenstein YY, Gross PL, Hamburg NM, Haniffa R, Hanna G, Hanna N, Hegde SM, Hendrickson CM, Hite RD, Hindenburg AA, Hope AA, Horowitz JM, Horvat CM, Hudock K, Hunt BJ, Husain M, Hyzy RC, Iyer VN, Jacobson JR, Jayakumar D, Keller NM, Khan A, Kim Y, Kindzelski AL, King AJ, Knudson MM, Kornblith AE, Krishnan V, Kutcher ME, Laffan MA, Lamontagne F, Le Gal G, Leeper CM, Leifer ES, Lim G, Lima FG, Linstrum K, Litton E, Lopez-Sendon J, Lopez-Sendon Moreno JL, Lother SA, Malhotra S, Marcos M, Saud Marinez A, Marshall JC, Marten N, Matthay MA, McAuley DF, McDonald EG, McGlothlin A, McGuinness SP, Middeldorp S, Montgomery SK, Moore SC, Morillo Guerrero R, Mouncey PR, Murthy S, Nair GB, Nair R, Nichol AD, Nunez-Garcia B, Pandey A, Park PK, Parke RL, Parker JC, Parnia S, Paul JD, Perez Gonzalez YS, Pompilio M, Prekker ME, Quigley JG, Rost NS, Rowan K, Santos FO, Santos M, Olombrada Santos M, Satterwhite L, Saunders CT, Schutgens REG, Seymour CW, Siegal DM, Silva DG Jr, Shankar-Hari M, Sheehan JP, Singhal AB, Solvason D, Stanworth SJ, Tritschler T, Turner AM, van Bentum-Puijk W, van de Veerdonk FL, van Diepen S, Vazquez-Grande G, Wahid L, Wareham V, Wells BJ, Widmer RJ, Wilson JG, Yuriditsky E, Zampieri FG, Angus DC, McArthur CJ, Webb SA, Farkouh ME, Hochman JS, Zarychanski R. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med. 2021 Aug 26;385(9):790-802. doi: 10.1056/NEJMoa2105911. Epub 2021 Aug 4.

    PubMed 34351721

  • Arabi YM, Gordon AC, Derde LPG, Nichol AD, Murthy S, Beidh FA, Annane D, Swaidan LA, Beane A, Beasley R, Berry LR, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Buxton M, Buzgau A, Cheng A, De Jong M, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Fowler R, Girard TD, Goligher EC, Goossens H, Haniffa R, Higgins AM, Hills TE, Horvat CM, Huang DT, King AJ, Lamontagne F, Lawler PR, Lewis R, Linstrum K, Litton E, Lorenzi E, Malakouti S, McAuley DF, McGlothlin A, Mcguinness S, McVerry BJ, Montgomery SK, Morpeth SC, Mouncey PR, Orr K, Parke R, Parker JC, Patanwala AE, Rowan KM, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Tong SYC, Turgeon AF, Turner AM, Van de Veerdonk FL, Zarychanski R, Green C, Berry S, Marshall JC, McArthur C, Angus DC, Webb SA; REMAP-CAP Investigators. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Med. 2021 Aug;47(8):867-886. doi: 10.1007/s00134-021-06448-5. Epub 2021 Jul 12.

    PubMed 34251506

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Ceftriaxone, Moxifloxacin or Levofloxacin and Piperacillin-tazobactam in people with Community-acquired Pneumonia, Influenza, COVID-19, run by UMC Utrecht at 408 sites in 29 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 12 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 408 sites in United Kingdom, Australia, Canada, France, Netherlands and 24 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Cameron Green, MSc (info@remapcap.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

All-cause mortality (time frame: Day 90). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02735707, which also lists 20 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jul 2024.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in